226 related articles for article (PubMed ID: 15909255)
1. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
[TBL] [Abstract][Full Text] [Related]
2. [Miltefosine for disseminated cutaneous leishmaniasis].
González LM; Vélez ID
Biomedica; 2006 Oct; 26 Suppl 1():13-6. PubMed ID: 17361837
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
4. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Sindermann H; Engel KR; Fischer C; Bommer W;
Clin Infect Dis; 2004 Nov; 39(10):1520-3. PubMed ID: 15546090
[TBL] [Abstract][Full Text] [Related]
5. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Zerpa O; Ulrich M; Blanco B; Polegre M; Avila A; Matos N; Mendoza I; Pratlong F; Ravel C; Convit J
Br J Dermatol; 2007 Jun; 156(6):1328-35. PubMed ID: 17441955
[TBL] [Abstract][Full Text] [Related]
6. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
7. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
8. Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.
Khandpur S; Chaturvedi P; Kumar U; Khaitan BK; Samantaray JC; Sharma VK
Int J Dermatol; 2010 May; 49(5):565-9. PubMed ID: 20534094
[No Abstract] [Full Text] [Related]
9. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
Hamzavi SS; Sanaei Dashti A; Kadivar MR; Pouladfar G; Pourabbas B
Pediatr Infect Dis J; 2018 Mar; 37(3):275-277. PubMed ID: 29424815
[TBL] [Abstract][Full Text] [Related]
11. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
12. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS.
Calza L; D'Antuono A; Marinacci G; Manfredi R; Colangeli V; Passarini B; Orioli R; Varoli O; Chiodo F
J Am Acad Dermatol; 2004 Mar; 50(3):461-5. PubMed ID: 14988693
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report.
Zerpa O; Blanco B; Kannee C; Ulrich M; Sindermann H; Engel J; Convit J
Int J Dermatol; 2006 Jun; 45(6):751-3. PubMed ID: 16796642
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of a married couple for American leishmaniasis with miltefosine.
Wöhrl S; Schnedl J; Auer H; Walochnik J; Stingl G; Geusau A
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):258-9. PubMed ID: 18211436
[No Abstract] [Full Text] [Related]
15. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
[TBL] [Abstract][Full Text] [Related]
16. Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.
Gianotti N; Maillard M; Gaiera G; Bestetti A; Cernuschi M; De Bona A; Lazzarin A; Cinque P; Bossolasco S
New Microbiol; 2008 Jul; 31(3):435-8. PubMed ID: 18843901
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine.
Aichelburg AC; Walochnik J; Assadian O; Prosch H; Steuer A; Perneczky G; Visvesvara GS; Aspöck H; Vetter N
Emerg Infect Dis; 2008 Nov; 14(11):1743-6. PubMed ID: 18976559
[TBL] [Abstract][Full Text] [Related]
18. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
19. [Diffuse cutaneous leishmaniasis in a patient with AIDS].
Pérez C; Solías Y; Rodríguez G
Biomedica; 2006 Dec; 26(4):485-97. PubMed ID: 17315475
[TBL] [Abstract][Full Text] [Related]
20. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
